Please check your internet connection and try again.
# Tussinex (Hydrocodone/Chlorpheniramine)
## Overview
Tussinex is a long-acting, extended-release oral suspension containing an opioid antitussive (hydrocodone polistirex) and a first-generation antihistamine (chlorpheniramine polistirex). The "qd" formulation utilizes an ion-exchange resin matrix to provide sustained release over 12 to 24 hours.
## Primary Indications
Symptomatic relief of cough and upper respiratory symptoms associated with allergies or the common cold.
## Adult Dosing
* **Dose:** 10 mL (containing 10 mg hydrocodone/8 mg chlorpheniramine) orally as a single daily dose.
* **Maximum:** 10 mL per 24 hours. Do not exceed the prescribed dose.
## Pediatric Dosing
* **Children 6 to 12 years:** 5 mL orally as a single daily dose.
* **Children < 6 years:** Safety and efficacy have not been established. Use is generally not recommended due to risk of respiratory depression.
## Dose Adjustments
* **Renal/Hepatic Impairment:** No specific guidelines exist for the combination; however, use caution and consider lower starting doses or extended dosing intervals due to the potential for hydrocodone accumulation.
* **Geriatric Patients:** Start at the lower end of the dosing range; increased sensitivity to CNS-depressant effects is common.
## Contraindications
* Hypersensitivity to hydrocodone, chlorpheniramine, or any product component.
* Patients with known or suspected paralytic ileus.
* Use within 14 days of MAO inhibitor therapy (risk of hypertensive crisis/serotonin syndrome).
* Presence of acute respiratory depression or severe asthma.
## Adverse Effects
* **CNS:** Sedation, dizziness, confusion, impaired coordination.
* **Gastrointestinal:** Constipation (very common), nausea, vomiting, xerostomia (dry mouth).
* **Respiratory:** Respiratory depression (dose-dependent).
* **Anticholinergic:** Urinary retention, blurred vision, tachycardia.
## Key Drug Interactions
* **CNS Depressants:** Alcohol, benzodiazepines, and other opioids significantly increase the risk of profound sedation, respiratory depression, and coma.
* **MAO Inhibitors:** Contraindicated.
* **Anticholinergics:** May lead to additive effects, including increased risk of urinary retention and ileus.
## Monitoring
* Monitor respiratory rate, especially in patients with underlying pulmonary disease.
* Assess for excessive sedation or cognitive impairment.
* Monitor bowel habits to prevent or treat constipation.
* Observe for signs of urinary retention.
## Clinical Pearls
* **Mechanism:** Hydrocodone acts centrally on the cough center in the medulla. Chlorpheniramine acts as an H1-receptor antagonist and possesses anticholinergic properties.
* **Handling:** Shake the suspension well before each dose to ensure uniform concentration of the resin-bound medication.
* **Abuse Potential:** Hydrocodone is a Schedule II controlled substance. Counsel patients on the high risk of dependence and misuse.
* **Safety:** Do not use with other cough/cold products containing antihistamines or opioids to prevent accidental overdose.
***
**Educational Disclaimer:** This information is for educational purposes only. Drug dosing and safety information can change based on regional guidelines, clinical updates, and specific patient factors. Always verify prescribing information through official resources (e.g., FDA-approved product labels, clinical pharmacy databases, or institutional protocols) before administration.
